-
FibroGen receives China approval for AstraZeneca unit sale
-
FibroGen (FGEN) Misses Q2 EPS by $1.79
-
FibroGen reaches FDA agreement on Phase 3 trial design for roxadustat
-
FibroGen (FGEN) Announces 1-for-25 Reverse Stock Split
-
FibroGen (FGEN) Appoints Michael Kauffman to its Board
-
FibroGen (FGEN) Tops Q1 EPS by 15c
-
FibroGen (FGEN) Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246
-
FibroGen (FGEN) Tops Q4 EPS by 35c
-
H.C. Wainwright Reiterates Buy Rating on FibroGen (FGEN)
-
FibroGen (FGEN) Sells FibroGen China to AstraZeneca (AZN) for $160M
-
H.C. Wainwright Starts FibroGen (FGEN) at Buy
-
FibroGen (FGEN) Appoints David DeLucia as CFO
-
FibroGen (FGEN) Tops Q3 EPS by 14c, Misses on Revenue; Offers FY24 Revenue Guidance
-
FibroGen (FGEN) Tops Q2 EPS by 16c ; Offers Guidance
-
Increasing unusual put option volume: FGEN LSCC GPN SHW MAR TELL ALAB
-
FibroGen (FGEN) PT Lowered to $0.60 at Goldman Sachs
-
Increasing unusual put volume: FGEN TELL NDAQ PTEN BK CRWD COPX
-
FibroGen (FGEN) Files $300M Mixed Shelf

